Uncertainty abounds following the collapse of the GOP effort to repeal and replace the Affordable Care Act.

Sign up for 30 days of no-obligation access to Inside Health Policy for all the essential news during this critical time.

Top Story

Nevada Health Link Criticizes GOP Health Reform Bill; Urges CSR Funding, Mandate Penalty

Nevada's Silver State Health Insurance Exchange says the American Health Care Act's continuous coverage requirement, new tax credits and lack of clarity around cost-sharing reduction payments would lead to higher costs for consumers, insurer uncertainty and increased uncompensated care for hospitals.

Latest News

Oregon state Democrats' language in an April 18 discussion document on elimination of the state's Medicaid expansion among the potential cuts was not intended as a recommendation, state Rep. Nancy Nathanson (D) told Inside Health Policy.

Democratic congressional leadership is pushing to bail out Puerto Rico's Medicaid program through the budget omnibus bill, a Democratic leadership aide told Inside Health Policy.

The White House Office of Management and Budget met with federal agencies Friday to prepare for a possible government shutdown should Congress doesn't pass a new spending bill when the Continuing Resolution runs out April 28, but HHS' prior contingency plan shows that many of CMS' functions would continue using mandatory funding.

FDA's recent high-profile clearance of genetic health risk tests by 23andMe brought with it a first-ever requirement that a sponsor create an opt-in page on its website -- previewing what potentially could reappear as the agency looks to exempt other GHR tests from device pre-market reviews.

The American Academy of Pediatrics laid out priorities for user fee reauthorization that would expand on the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA), including making permanent the BPCA's National Institutes of Health program that funds studies on use of off-patent drugs in children.

President Trump on Friday (April 21) backed off a White House push to score a legislative victory on health reform next week ahead of his 100th day in office, telling reporters that “it doesn't matter” if the vote is next week, or any other week.

FDA announced Friday (April 21) approval of Samsung Bioepsis Co LTD's biosimilar for Remicade, which appears to be the first biosimilar approved without an advisory committee weighing in, as well as the first biologic product to follow FDA's biologic naming scheme after the agency finalized the convention in January.

The White House budget office met with federal agencies Friday (April 21) to prepare for a possible government shutdown should Congress not pass a new spending bill when the Continuing Resolution expires in a week.